Taysha gene therapies announces two poster presentations on tsha-102 in rett syndrome at upcoming european society of gene & cell therapy (esgct) 30th annual congress

Dallas, oct. 10, 2023 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns), today announced that it will present data on its tsha-102 program in evaluation for rett syndrome during two poster presentations at the european society of gene & cell therapy (esgct) 30th annual congress, taking place in brussels, belgium from october 24-27, 2023.
TSHA Ratings Summary
TSHA Quant Ranking